{
    "symbol": "XGN",
    "quarter": 3,
    "year": 2022,
    "date": "2022-11-14 22:25:13",
    "content": " All forward-looking statements, including, without limitation, statements regarding our business strategy and future financial and operating performance, including 2022 guidance, our current and future product offerings, and reimbursement and coverage, restatement of our financial statements for the second quarter of 2022 and our plan for remediation with respect to the one or more material weaknesses in internal controls over financial reporting that we expect to identify are based upon current estimates and various assumptions. The $2.9 million decrease in year-over-year revenue is primarily due to a decrease of $1.4 million in AVISE CTD testing due to lower ASPs, partially offset by an increase in volume, a $1 million decrease due to the termination of the SIMPONI agreement and a $0.5 million decrease from other testing. Please proceed with your question. Please proceed with your question. Please proceed with your question. Please proceed with your question."
}